Peripheral artery disease (PAD) poses a great challenge to society, with a growing
prevalence in the upcoming years. Patients in the severe stages of PAD are prone to …

Metabolic comorbidities are common in patients with cardiorenal disease; they can cause
atherosclerotic cardiovascular disease (ASCVD), speed progression, and adversely affect …

Objective Acute limb ischemia (ALI), the most challenging form of ischemia-reperfusion
injury (IRI) in skeletal muscle tissue, leads to decreased skeletal muscle viability and limb …

Critical limb ischemia (CLI), the terminal stage of peripheral arterial disease (PAD), is
characterized by an extremely high risk of amputation and vascular issues, resulting in …

Therapeutic angiogenesis with mesenchymal stem cells (MSCs) is promising for the clinical
treatment of peripheral artery disease (PAD). However, the heterogeneous proangiogenic …

Critical limb ischemia (CLI) constitutes the most severe form of peripheral arterial disease
(PAD), it is characterized by progressive blockade of arterial vessels, commonly correlated …

Therapies based on injecting living cells into patients offer a huge potential to cure many
degenerative and deadly diseases, with hundreds of clinical trials ongoing. Due to their …

Peripheral artery disease is a common disorder and a major cause of morbidity and mortality
worldwide. Therapy is directed at reducing the risk of major adverse cardiovascular events …

Progressive peripheral arterial disease (PAD) can result in chronic limb-threatening
ischemia (CLTI) characterized by clinical complications including rest pain, gangrene and …

Background and Purpose—Bone marrow mononuclear cells (BM-MNCs) are a rich source
of hematopoietic stem cells and have been widely used in experimental therapies for …